Skip to main content
. 2016 Aug 16;18(10):843–850. doi: 10.1016/j.hpb.2016.07.008

Table 2.

Potential prognostic clinicopathologic factors for DFS and OS for (a) entire cohort and (b) cohort stratified by margin status

(a)
UVA
 MVA
 UVA
 MVA
Factors HR (DFS) p-Value HR (DFS) p-Value HR (OS) p-Value HR (OS) p-Value
Age 1.01 (0.99–1.03) 0.41 1.02 (0.99–1.04) 0.21
Female 1.14 (0.70–1.85) 0.59 0.88 (0.52–1.49) 0.62
Location Reference: Intrahepatic 0.93 Reference: Intrahepatic 0.51
 Perihilar 1.00 (0.55–1.83) 1.15 (0.59–2.23)
 Distal 1.10 (0.64–1.90) 1.41 (0.79–2.53)
Tumor stagea Reference: T1 0.003 Reference: T1 0.005
 T2 1.67 (0.89–3.15) 1.81 (0.91–3.63)
 T3–4 2.81 (1.55–5.07) 2.96 (1.54–5.67)
≥1 nodea 2.03 (1.23–3.36) 0.006 2.55 (1.49–4.37) <0.001
Group stage Reference: I 0.003 0.002 Reference: I 0.010 0.003
 II 1.21 (1.02–3.23) 2.08 (1.14–3.77) 2.21 (1.19–4.11) 2.74 (1.44–5.20)
 III/IV 2.92 (1.59–5.35) 2.96 (1.61–5.44) 2.61 (1.33–5.10) 2.79 (1.41–5.52)
R1 vs R0 1.61 (0.98–2.65) 0.06 1.90 (1.13–3.22) 0.01 1.63 (0.96–2.75) 0.07 2.00 (1.14–3.51) 0.01
ECE 1.63 (0.59–4.55) 0.35 1.06 (0.33–3.42) 0.95
LVSI 1.43 (0.71–2.89) 0.32 1.58 (0.77–3.26) 0.21
PNS 1.16 (0.70–1.92) 0.56 1.34 (0.79–2.27) 0.27
DF vs LF 1.21 (0.58–2.50) 0.62
aCRT 0.66 (0.38–1.16) 0.13 0.47 (0.26–0.87) 0.01 0.56 (0.30–1.06) 0.07 0.33 (0.17–0.66) 0.002
(b)
Factors UVA
 MVA
 UVA
 MVA
HR (DFS) p-Value HR (DFS) p-Value HR (OS) p-Value HR (OS) p-Value
R0 Age 1.01 (0.98–1.04) 0.59 1.02 (0.99–1.05) 0.26
Female 1.16 (0.63–2.11) 0.63 0.82 (0.42–1.61) 0.57
ECOG 2 vs ≤1 1.07 (0.45–2.58) 0.88 1.37 (0.56–3.33) 0.49
Location Reference: Intrahepatic 0.78 Reference: Intrahepatic 0.50
 Perihilar 1.19 (0.54–2.62) 1.40 (0.59–3.35)
 Distal 1.27 (0.65–2.47) 1.54 (0.74–3.22)
Tumor stagea Reference: T1 0.030 Reference: T1 0.013
 T2 1.62 (0.74–3.56) 1.78 (0.75–4.25)
 T3–4 2.69 (1.30–5.58) 3.37 (1.48–7.64)
≥1 nodea 2.13 (1.14–3.98) 0.018 2.51 (1.27–4.97) 0.008
Group stage Reference: I 0.06 0.01 Reference: I 0.029 0.009
 II 1.99 (1.00–3.96) 2.62 (1.26–5.44) 2.64 (1.26–5.52) 3.25 (1.48–7.13)
 III–IV 2.32 (1.07–5.04) 2.68 (1.21–5.93) 2.40 (0.98–5.85) 2.93 (1.17–7.33)
ECE 1.61 (0.38–6.80) 0.51 0.92 (0.13–6.83) 0.94
LVSI 2.06 (0.73–5.88) 0.17 2.40 (0.81–7.12) 0.11 3.01 (1.03–8.83) 0.045 3.10 (1.01–9.52) 0.05
PNS 1.63 (0.84–3.17) 0.15 1.60 (0.81–3.18) 0.18 2.17 (1.09–4.34) 0.028 2.03 (0.98–4.18) 0.06
DF vs LF 0.81 (0.30–2.22) 0.69
aCRT 0.52 (0.22–1.23) 0.13 0.34 (0.13–0.85) 0.020 0.56 (0.22–1.44) 0.23 0.34 (0.13–0.93) 0.04
R1 Age 1.01 (0.97–1.05) 0.68 1.00 (0.96–1.04) 0.96
Female 1.15 (0.51–2.60) 0.74 0.82 (0.34–1.96) 0.65
ECOG 2 vs ≤1 2.63 (1.10–6.30) 0.03 7.22 (2.35–22.20) <0.001 2.35 (0.96–5.74) 0.06 4.85 (1.59–14.84) 0.006
Location Reference: Intrahepatic 0.72 Reference: Intrahepatic 0.90
 Perihilar 0.71 (0.27–1.87) 1.10 (0.39–3.12)
 Distal 0.72 (0.27–1.90) 1.27 (0.47–3.43)
Tumor stagea Reference: T1 0.090 Reference: T1 0.29
 T2 1.45 (0.49–4.35) 2.11 (0.67–6.70)
 T3–4 2.95 (1.06–8.21) 2.32 (0.78–6.91)
≥1 nodea 1.63 (0.70–3.80) 0.26 2.34 (0.98–5.60) 0.056
Group stage Reference: I 0.006 0.002 Reference: I 0.26 0.09
 II 1.32 (0.44–3.94) 2.09 (0.63–6.97) 1.69 (0.52–5.37) 2.93 (0.83–10.39)
 III/IV 5.09 (1.70–15.29) 10.56 (2.68–41.61) 2.47 (0.83–7.31) 4.06 (1.14–14.41)
ECE 1.57 (0.35–7.06) 0.55 0.80 (0.18–3.53) 0.77
LVSI 0.87 (0.29–2.58) 0.80 0.81 (0.27–2.41) 0.71
PNSb 0.39 (0.17–0.89) 0.03 0.24 (0.09–0.67) 0.01 0.31 (0.13–0.76) 0.011 0.09 (0.03–0.39) 0.001
DF vs LF 3.89 (0.89–16.97) 0.071
aCRT 0.55 (0.23–1.28) 0.17 0.69 (0.27–1.79) 0.45 0.38 (0.15–0.94) 0.036 0.15 (0.05–0.53) 0.003

UVA, univariable analyses; MVA, multivariable analyses; HR, hazard ratio; ECE, extracapsular extension; LVSI, lymphovascular space invasion; PNS, perineural spread; R1, positive margin; R0, negative margin; aCRT, adjuvant chemoradiation; DF, distant failure; LF, local failure; ECOG, Eastern Cooperative Oncology Group performance status.

a

Not included in MVA to avoid co-linearity with group staging.

b

aCRT was employed on 6/12 (50%) with PNS as opposed to 6/16 (37.5%) without PNS.